MAP2K7 and melanoma: One hit that was both projected to be active by Ingenuity Pathway Analysis and was also elevated in melanoma was FOXM1 (Figure 1a), a MEK target.11 We found FOXM1 to correlate with progressive disease status (Figure 1b), suggesting FOXM1 may be relevant to melanoma development.